Form S-8 Mersana Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Mersana (MRSN) PT Lowered to $11 at Wedbush
March 12, 2019 7:19 AM EDTWedbush analyst David Nierengarten lowered the price target on Mersana (NASDAQ: MRSN) to $11.00 (from $15.00) while maintaining a Outperform rating.
Ph 1b dose escalation data from MRSNs XMT-1536 is expected in 2Q19MRSN set to unveil their next clinical candidate in H2:19... More
